Title: Chemical Glycobiology Studies on Bacterial Pseudaminic Acid
Professor Xuechen Li received his Ph.D. from Harvard University in 2007. After postdoctoral work in the laboratory of Prof. Samuel Danishefsky at the Memorial Sloan Kettering Cancer Center in New York, he joined the Department of Chemistry at the University of Hong Kong as an Assistant Professor in 2009 and was promoted to Associate Professor in 2014 and Professor in 2018. He currently serves as the Associate Dean (Research & Graduate Studies) of Faculty of Science. The central theme of Professor Li’s research focuses on the chemical biology of synthetic biomolecules (proteins, carbohydrates, and glycoconjugates) to study fundamental biological questions and develop potential therapeutic applications.
Title: Galectins, Atg8ylation, and Stress Granules in Autophagy and Membrane Stress Response
Dr. Vojo Deretic is the department chair of the Department of Molecular Genetics and Microbiology at the University of New Mexico School of Medicine and the director of the NIH-funded Autophagy, Inflammation and Metabolism (AIM) Center of Biomedical Research Excellence. The AIM center aims to promote autophagy research nationally and internationally and to develop a cadre of junior faculty along with senior experts in this area to study fundamental mechanisms and how autophagy intersects with a broad spectrum of human disease and health states. He received his undergraduate, graduate, and postdoctoral education in Belgrade, Paris, and Chicago. Dr. Deretic’s main contributions to science come from studies by his team on the role of autophagy in infection, immunity, and inflammation. Recently, Dr. Deretic’s group developed the concept of a cellular system termed MERIT for coordinated membrane repair, removal, and replacement. This involves recognition of exposed glycoconjugates on damaged membranes, membrane repair, removal of membranes by autophagy, and replacement of membranous organelles through respective biogenesis programs.
Title: C-Mannosylation of Proteins: Specificity and Function
Dr. Hans Bakker is a glycobiologist with expertise in glycosyltransferases. He received his Ph.D. at the VU Amsterdam, the Netherlands, and worked in Zurich, Switzerland, and Wageningen, the Netherlands, afterwards. Since 2001, he has worked at Hannover Medical School in Germany. Over the years, he has identified several new genes encoding glycosyltransferases, including the xylosyltransferases responsible for the glycosylation of Notch EGF repeats and, more recently, the first C-mannosyltransferase, the enzyme responsible for unique glycosylation of tryptophans in proteins. His laboratory has established several specific methods to characterize C-mannosyltransferases and their target proteins from Caenorhabditis elegans and mammals in vitro and cellular systems. After cloning the C-mannosyltransferase in 2013, he could establish that C-mannosylation assists in protein folding in the endoplasmic reticulum and is important for the temperature stability of proteins. Whereas C. elegans has one C- mannosyltransferase, four homologs are present in mammals. His group could show that different mammalian C-mannosyltransferases have distinct fine specificity.
Title: Targeting Human Viruses with Broadly Protective Low-Sugar Vaccines
Professor Wong received his B.S. and M.S. degrees from National Taiwan University, and Ph.D. (1982) in Chemistry from MIT. He then worked at Harvard University as a postdoctoral fellow, became an assistant professor at Texas A&M University in 1983, and became a professor in 1987. He was Professor and Ernest W. Hahn Chair in Chemistry at the Scripps Research Institute (1989–2006), Director of Genomics Research Center (2003–2006), and President of Academia Sinica (2006-2016). He is currently the Scripps Family Chair Professor of Chemistry at The Scripps Research Institute with a joint appointment at Genomics Research Center, Academia Sinica.
Professor Wong receives numerous awards, including the U.S. Presidential Green Chemistry Challenge Award, the ACS Claude Hudson Award in Carbohydrate Chemistry, Creative Work in Synthetic Organic Chemistry, and the Cope Medal, the Wolf Prize in Chemistry. He is a member of Academia Sinica, the American Academy of Arts and Sciences, and the U.S. National Academy of Sciences.
His research interests are in the field of chemical biology and synthetic chemistry, including the synthesis of complex carbohydrates and glycoproteins associated with disease progression. He is the author of over 700 publications (H-index 144) and 100 patents.
Title: Leveraging tumor-associated alterations in O-glycosylation for cancer immunotherapy
Dr. Avery Posey is an Assistant Professor at the University of Pennsylvania Perelman School of Medicine. He received Ph.D. from the University of Chicago (2011) and his postdoctoral training at the University of Pennsylvania. He is a classically trained molecular and developmental geneticist and an expert in the development and pre-clinical characterization of chimeric antigen receptors (CARs) and other engineered T cell strategies for cancer immunotherapy. His current research is focused on the redirection of T cells to target cancer-specific epitopes, especially glycan haptens and O-glycopeptide epitopes formed through altered glycosylation in cancer cells, investigation of optimal CAR-T signaling for effective anti-tumor responses and durable persistence in solid tumors, and CRISPR/Cas9-mediated gene-editing strategies for improved engineered T cells (knockout of checkpoint molecules - PD-1, CTLA-4, etc.; HDR knock-in of combination therapies). The major objective of his research is to increase the efficacy of engineered T cells in solid tumors.
Title: Glycans at the Frontiers of Inflammation, Autoimmunity and Cancer: mechanisms and clinical implications.
Salomé Pinho is the coordinator of the research group "Immunology, Cancer & GlycoMedicine" at the Institute for Research and Innovation in Health (i3S) at the University of Porto, Portugal, and affiliated Professor at the Medical Faculty of the University of Porto, Portugal. She developed her Ph.D. research at the Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) and Boston University Medical School, MA, USA. She performed her postdoctoral work at IPATIMUP-University of Porto in the cancer glycobiology field. Early in her career, Dr. Pinho established a research line focusing on glycoimmunology in Inflammatory Bowel Disease. Her group focuses on understanding the role of post-translational modifications by glycosylation in the regulation of key proteins´ functions involved in cancer and chronic inflammatory conditions, envisioning potential clinical applications.
She is the Principal Investigator of several national/international grants in cancer glycobiology and inflammatory diseases. She received the Young Investigator Award from the European Association for Cancer Research and was recently distinguished by the Society for Glycobiology with the 2020 Glycobiology Significant Achievement Award.
Dr. Linda Hsieh-Wilson is a Professor of Chemistry at the California Institute of Technology. She was born in New York City and obtained her B.S. degree magna cum laude in chemistry from Yale University in 1990. In 1996, she received her Ph.D. in chemistry from the University of California at Berkeley, where she was a National Science Foundation predoctoral fellow in the laboratory of Professor Peter Schultz. In 1996, she moved to Rockefeller University to study neurobiology with Professor and Nobel Laureate Paul Greengard as a Damon Runyon-Walter Winchell postdoctoral fellow. Hsieh-Wilson joined the faculty at the California Institute of Technology in 2000, where she became an associate professor of chemistry in 2006 and a full professor in 2010. She was an Investigator at the Howard Hughes Medical Institute from 2005-2014, and in 2015, she was elected to the American Academy of Arts and Sciences.
Professor Hsieh-Wilson has pioneered the application of organic chemistry to understand the roles of carbohydrates and protein glycosylation in neurobiology. Her honors include a Beckman Young Investigator Award (2000), Research Corporation Research Innovation Award (2000), Alfred P. Sloan Fellowship (2003), Eli Lilly Award in Biological Chemistry (2006), Arthur C. Cope Scholar Award (2008), Gill Young Investigator Award in Neuroscience (2009), and Horace S. Isbell Award in Carbohydrate Chemistry (2014).
Chang Gung Memorial Hospital and University, Taiwan
Title: Cancer immunotherapy targeting glycosphingolipids (GSLs)
Alice L. Yu, MD, PhD, is an Academician of Academia Sinica, Taiwan. She is a Distinguished Chair Professor & Deputy Director of the Institute of Stem Cell & Translational Cancer Research at Chang Gung Memorial Hospital and Professor Emeritus at the University of California in San Diego.
As a pioneer in cancer immunotherapy, Dr. Yu has taken an anti-GD2 monoclonal antibody (Dinutuximab) from preclinical to phase III clinical trial, culminating in its FDA approval for the treatment of high-risk neuroblastoma in 2015. This marks the first immunotherapeutic agent to target glycolipids worldwide. She has continued to improve the efficacy of anti-GD2 immunotherapy through international collaboration. Her group has demonstrated the adverse impact of Globo H expression on the outcome of patients with hepatoma, cholangiocarcinoma, and gallbladder cancer. She also uncovered the roles of Globo H in cancer as an immune checkpoint molecule and angiogenic factor, providing rationales for the ongoing development of Globo H-targeted immunotherapeutics.
She has received many awards, including the Pediatric Oncology Award from the American Society of Clinical Oncology (ASCO) in 2020, Excellence in Technology Transfer Award from Federal Laboratory Consortium (USA) in 2016, The 55th Academic Award from the Ministry of Education (Taiwan), Year 2000 "Key to Life" Award, Leukemia & Lymphoma Society (USA), etc.
Title: Regulation and Protein Selectivity of N-Glycan Branching Enzymes
Professor Yasuhiko Kizuka has been a researcher at Disease Glycomics Team, RIKEN, led by Dr. Naoyuki Taniguchi (2009-2017). He has joined Gifu University (Japan) as an Associate Professor since 2017, and is currently the Director and Professor of Integrated Glyco-Molecular Science Center, Institute for Glyco-core Research (iGCORE) at Gifu University.
Professor Kizuka’s glyco-related contributions include discovery of novel mode of catalytic action of glycosyltransferases, elucidation of glycosyltransferase structures and development of glycosyltransferase inhibitors. His Research Interests are (1) Regulation of glycosyltransferase activity; (2) Substrate protein selectivity of glycosyltransferases; (3) Physiological functions of N-glycan branches.
Title: Glycosyl Hydrolases from the Seeds of Cucurbitaceae
Professor Nadimpalli is a Senior Professor in Biochemistry at University of Hyderabad, Hyderabad, India. He did his postdoctoral training at DAAD, Wuerzburg and Goettingen, Germany, and has been a faculty at University of Hyderabad since 1986.
His glyco-related contributions include development of novel affinity methods to purify mannose 6-phosphate receptors, discovery of LERP from Drosophila and lysosomal enzymes and their receptors in Hydra. He also identified and purified several plant and animal glycosidases, contributed towards understanding the physiological significance of Cucurbitaceae seed lectins and glycosidases.
His Research Interests are (1) Evolution of lysosomal biogenesis; (2) Legume and non-legume lectins-structure-function relationships; (3) Physiological functions of Plant lectins and glycosidases from legumes and non-legumes.
@TAIPEI, AUG 27~SEP 1 2023
To learn more about each individual speaker, please click on the photos below.
Professor Henrik Clausen is the Director of the Copenhagen Center for Glycomics. He has been working in the glycoscience field for 30 more years focusing on the structure, biosynthesis, and genetic regulation of complex carbohydrates. He studied with Professor Sen-Itiroh Hakomori in Seattle (1983-90) on blood group-related carbohydrates, glycosyltransferases, and genes.
He is a member of scientific advisory boards and consultant for Neose Technologies, ZymeQuest Inc, GlycoZym Inc, and GlycoDisplay Aps. Professor Clausen is a national representative for the International Glycoconjugate Organization (IGO) and a member of the Royal Danish Academy of Sciences and Letters.
His research focus is primarily on protein glycosylation with early contributions to isolation, cloning, and expression of many of the human glycosyltransferases involved in the biosynthesis of human glycans and especially mucin-type glycans. His group developed strategies to isolate and characterize O-glycoproteomes by use of nuclease-mediated gene engineering - the SimpleCell approach. He applies genetic engineering of the glycosylation capacities in mammalian cells for de/reconstruction of glycosylation, dissection of biological functions of glycans, and custom-design of recombinant glycoprotein therapeutics. He also applies this strategy to develop cell-based glycan arrays and, most recently, the first display of human mucin O-glycodomains.
Dr. Drickamer began working in the field of glycan-binding receptors as a postdoctoral fellow at Duke University. These receptors have been the focus of his subsequent research at Cold Spring Harbor Laboratory, the University of Chicago, Columbia University, Oxford University, and currently at Imperial College London. His work on identifying a common carbohydrate recognition led to the definition of C-type lectins as one of the major groups of glycan-binding receptors. His ongoing research is a joint project with Dr. Maureen Taylor. The aim is to develop a broad understanding of the biological roles of sugar recognition. They have used a combination of biochemical, biophysical, and molecular biological approaches to understand how carbohydrate-recognition domains provide selective recognition of glycoproteins and cell surfaces. In addition, they seek to determine how such recognition leads to the targeting of biological functions, such as innate immunity to pathogens, clearance of serum glycoproteins, cell adhesion, and cell signaling, and how genetic variation in sugar-binding receptors causes changes in their molecular properties and hence contributes to human disease. Dr. Taylor and Dr. Drickamer co-authored the textbook Introduction to Glycobiology, designed to introduce the field to students and researchers from other disciplines.
Anne Dell is Professor of Carbohydrate Biochemistry at Imperial College London. She joined Imperial College as a postdoc in 1975 after completing a PhD on peptide sequencing by mass spectrometry at the University of Cambridge. During the 1970’s and 1980’s, Anne was amongst the first investigators to apply soft ionisation mass spectrometry to carbohydrate containing biopolymers. Subsequently, she spearheaded the development of combined microchemical and mass spectrometric procedures for the identification of novel carbohydrate structures of biological and medical importance. Notably she introduced and optimised rapid techniques for characterising glycomes in a wide range of biological materials, including purified glycoproteins, body fluids, secretions, cells, tissues and organs. She has applied these procedures in worldwide collaborative research on bacterial, plant and mammalian polysaccharides, glycolipids and glycoproteins, thereby making a substantial contribution to current understanding of the functions of glycans. In particular, she has made important contributions to the structural glycobiology of mammalian sperm-egg recognition, glycan-lectin regulation of immune function, pathogen-host interactions and human reproductive glycobiology. A major focus of her current research, supported by the March of Dimes European Preterm Birth Research Centre at Imperial College, is aimed at understanding the roles that glycans play in preterm pregnancies.
Dr. Haltiwanger did his doctoral work under the direction of Dr. Robert Hill at Duke University, where he purified and characterized mammalian lectins (Fucose lectin, Mannose receptor). He moved to Dr. Gerald Hart’s lab at Johns Hopkins, where he purified and characterized O-GlcNAc transferase. He moved to Stony Brook University for his first independent appointment, where he rose through the ranks, ultimately as Chair of the Department of Biochemistry and Cell Biology. In 2015 he moved to the Complex Carbohydrate Research Center at the University of Georgia, where he is currently the Georgia Research Alliance Eminent Scholar in Biomedical Glycobiology. He has served as President of the Society for Glycobiology, Chair of the Glycobiology Gordon Conference, Editor of Glycobiology, and currently serves as Associate Editor for the Journal of Biological Chemistry. His laboratory works on unusual O-linked modifications found on two cysteine-rich modules: Epidermal Growth Factor-like (EGF) repeats and Thrombospondin Type 1 Repeats (TSRs). They have identified the enzymes that add O-fucose to EGF repeats (POFUT1) and to TSRs (POFUT2), as well as those that add O-glucose to EGF repeats (POGLUT1, 2, and 3). These enzymes are required for normal development in mice and humans. They have also worked on enzymes that elongate O-fucose on EGF repeats (Fringes) and TSRs (B3GLCT), all of which play important roles in biology. His laboratory continues to identify proteins modified by these enzymes and the effects of the modifications on their functions.
Dr. Daniel Kolarich is a research leader at the Institute for Glycomics, Griffith University, Queensland, Australia. His group is using Mass Spectrometry based techniques to understand the role of cell surface glycoconjugates, such as glycoproteins and glycolipids, in cell communication, cell signalling, host-pathogen interactions, and diseases such as cancer. Specific research interests include analytical tool development for glycomics and glycoproteomics, Vertebrata phyloglycomics, erythropoiesis, blood products, and stem cell biology, as well as applying glycomics and glycoproteomics to understand better the role of glycoconjugates in cancer and infectious diseases.
Originally from Vienna, Austria, he had the chance to learn from great mentors and scientists, from Vienna, where he received his education and Ph.D. via Sydney at Macquarie University and Berlin at the Max-Planck-Institute of Colloids and Interfaces before he finally landed at the Gold Coast to join the Institute for Glycomics. He has published over 140 peer-reviewed articles, is the vice president of the Australian Glycoscience Society, and is dedicated to promoting and integrating glycosciences.
The primary focus of Dr. Matthew Macauley’s laboratory is the immunomodulatory sialic acid-binding Siglec family of receptors. His group develops innovative approaches to probe Siglec-glycan interactions on cells and tissues and use new insights about the biological ligands of Siglecs to test hypotheses about the roles of Siglecs in controlling immune cell function.
Dr. Maureen Taylor started working on sugar-binding receptors, such as the mannose receptor of liver endothelial cells and macrophages, as a graduate student at the Royal Free Hospital in London. Her subsequent research at Columbia University, Oxford University, and Imperial College London has continued to focus on related members of the C-type lectin family of glycan-binding receptors. Dr. Taylor' s ongoing research is joint with Kurt Drickamer. They use techniques of biochemistry, structural biology, molecular biology, and cell biology to gain an understanding of the molecular mechanisms underlying the recognition of glycoproteins and cell surfaces by glycan-binding proteins and the biological functions mediated by carbohydrate recognition. Of particular interest are sugar-binding receptors on cells of the immune system, for example, DC-SIGN, langerin, and dectin-2, that recognize sugars found on pathogens and have roles in innate immunity, as well as receptors involved in glycoprotein homeostasis. They have also tried to make the field of glycobiology accessible to undergraduates and researchers from other disciplines by co-authoring the textbook Introduction to Glycobiology which has now been translated into three languages.
Professor Manfred Wuhrer studied Biochemistry at Regensburg University and obtained his Ph.D. in 1999 at Giessen University, Germany. Subsequently, he joined the Leiden University Medical Center, where he was appointed assistant professor in 2005 and associate professor in 2008. In 2013, he was appointed full professor of Analytics for Biomolecular Interactions at VU University Amsterdam. In 2015 he continued his career as Head of the Center for Proteomics and Metabolomics at LUMC, Leiden. He focuses on the development of mass spectrometric methods for glycomics and glycoproteomics and their application in clinical research and biotechnology. Clinical applications cover the fields of rheumatoid arthritis, inflammatory bowel disease, colorectal cancer, prostate cancer, longevity, as well as various infectious diseases.